TRIDENT LIFELINE Financial Statement Analysis
|
||
The Revenues of TRIDENT LIFELINE have increased by 40.82% YoY .
The Earnings Per Share (EPS) of TRIDENT LIFELINE has increased by 5.54 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
TRIDENT LIFELINE Last 5 Annual Financial Results
[BOM: 543616]
Consolidated | Mar2024 | Mar2023 | Mar2022 |
---|---|---|---|
Revenues | ₹45 Cr | ₹32 Cr | ₹22 Cr |
Expenses | ₹36 Cr | ₹25 Cr | ₹19 Cr |
Operating Profit (Excl OI) | ₹8.23 Cr | ₹6.27 Cr | ₹2.71 Cr |
Other Income | ₹2.08 Cr | ₹1.16 Cr | ₹0.60 Cr |
Interest | ₹0.65 Cr | ₹0.48 Cr | ₹0.13 Cr |
Depreciation | ₹0.97 Cr | ₹0.37 Cr | ₹0.20 Cr |
Profit Before Tax | ₹8.70 Cr | ₹6.58 Cr | ₹2.98 Cr |
Profit After Tax | ₹5.94 Cr | ₹6.02 Cr | ₹3.95 Cr |
Consolidated Net Profit | ₹6.34 Cr | ₹6.02 Cr | ₹3.95 Cr |
Earnings Per Share (Rs) | ₹5.52 | ₹5.23 | ₹4.93 |
PAT Margin (%) | 13.31 | 18.99 | 18.14 |
ROE(%) | 12.52 | 24.21 | 83.23 |
ROCE(%) | 15.32 | 23.60 | 43.21 |
Total Debt/Equity(x) | 0.37 | 0.17 | 0.52 |
Key Financials |
||
Market Cap | : | ₹ 286.9 Cr |
Revenue (TTM) | : | ₹ 47.5 Cr |
Net Profit(TTM) | : | ₹ 8.0 Cr |
EPS (TTM) | : | ₹ 7.0 |
P/E (TTM) | : | 35.8 |
Industry Peers & Returns | 1W | 1M | 1Y |
TRIDENT LIFELINE | -7% | -7.3% | 24.2% |
SUN PHARMACEUTICAL INDUSTRIES | 3.9% | -3.2% | 3.1% |
DIVIS LABORATORIES | 1.8% | -4.5% | 53.9% |
CIPLA | -0.6% | -0.3% | -2.4% |
TORRENT PHARMACEUTICALS | 1.2% | -3% | 14.9% |
DR REDDYS LABORATORIES | -3% | -9.5% | -11.7% |
MANKIND PHARMA | -4.6% | -13.5% | 2.6% |
ZYDUS LIFESCIENCES | -2% | -7.8% | -7.9% |
LUPIN | -2.7% | -9.4% | 18.4% |
TRIDENT LIFELINE Revenues
[BOM: 543616]
Y-o-Y | 40.82 % |
5 Yr CAGR | 43.19 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹45 Cr | 40.82 | |
Mar2023 | ₹32 Cr | 45.59 | |
Mar2022 | ₹22 Cr | - |
TRIDENT LIFELINE Operating Profit
[BOM: 543616]
Y-o-Y | 31.41 % |
5 Yr CAGR | 74.34 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹8.23 Cr | 31.41 | |
Mar2023 | ₹6.27 Cr | 131.30 | |
Mar2022 | ₹2.71 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -6.68 % |
5 Yr CAGR | 21.78 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 18.45% | -6.68 | |
Mar2023 | 19.77% | 58.92 | |
Mar2022 | 12.44% | - |
TRIDENT LIFELINE Profit After Tax
[BOM: 543616]
Y-o-Y | 5.47 % |
5 Yr CAGR | 26.76 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹6.34 Cr | 5.47 | |
Mar2023 | ₹6.02 Cr | 52.36 | |
Mar2022 | ₹3.95 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -29.91 % |
5 Yr CAGR | -14.34 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 13.31 % | -29.91 | |
Mar2023 | 18.99 % | 4.69 | |
Mar2022 | 18.14 % | - |
TRIDENT LIFELINE Earnings Per Share (EPS)
[BOM: 543616]
Y-o-Y | 5.54 % |
5 Yr CAGR | 5.81 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹5.52 | 5.54 | |
Mar2023 | ₹5.23 | 6.09 | |
Mar2022 | ₹4.93 | - |
TRIDENT LIFELINE Return on Capital Employed (ROCE)
[BOM: 543616]
Y-o-Y | -35.08 % |
5 Yr CAGR | -40.46 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 15.32% | -35.08 | |
Mar2023 | 23.6% | -45.38 | |
Mar2022 | 43.21% | - |
TRIDENT LIFELINE Share Price vs Sensex
Current Share Price | : | ₹249.5 |
Current MarketCap | : | ₹ 286.9 Cr |
Updated EOD on | : | Mar 12,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
TRIDENT LIFELINE | -7% |
-7.3% |
24.2% |
SENSEX | 0.4% |
-4.9% |
-0.1% |
TRIDENT LIFELINE related INDICES
You may also like the below Video Courses
FAQ about TRIDENT LIFELINE Financials
How the annual revenues of TRIDENT LIFELINE have changed ?
The Revenues of TRIDENT LIFELINE have increased by 40.82% YoY .
How the Earnings per Share (EPS) of TRIDENT LIFELINE have changed?
The Earnings Per Share (EPS) of TRIDENT LIFELINE has increased by 5.54 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs